Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Turkey / NCT07248072
Recruiting Not applicable

Effect of iPACK and BiFeS Blocks on Quality of Recovery After Total Knee Arthroplasty

NCT07248072 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2025-12-01
Last updated
2026-05-18

Condition(s) studied

Knee OsteoarthritisPostoperative Pain ManagementTotal Knee Arthroplasty

Investigational drug(s) / intervention(s)

Adductor Canal Block (ACB) OnlyIPACK blockBiFeS Block

Adductor Canal Block (ACB) Only: An ultrasound-guided adductor canal block (ACB) will be performed using 15 mL of 0.25% bupivacaine. The probe will be placed on the proximal thigh to visualize the sartorius muscle and femoral artery. The needle will be advanced in-plane into the adductor canal, and correct placement will be confirmed with 2 mL saline before injection. This block aims to provide anterior knee analgesia while preserving quadriceps strength.

IPACK block: The iPACK block will be performed by placing the ultrasound probe at the popliteal region to visualize the popliteal artery and posterior knee capsule. A needle will be advanced in-plane, and 25 mL of 0.25% bupivacaine will be injected between the artery and posterior capsule. This block targets posterior knee pain after total knee arthroplasty without causing motor block.

BiFeS Block: The BiFeS block will be performed with the ultrasound probe placed laterally to visualize the femur cortex and the long and short heads of the biceps femoris muscle. The needle will be advanced in-plane into the potential space between the femur and the short head of the biceps femoris. After confirming position with 2 mL saline, 25 mL of 0.25% bupivacaine will be injected. This block provides posterolateral knee analgesia with limited motor involvement.

Study summary

This prospective, randomized, double-blind clinical trial aims to compare the effects of two different posterior knee analgesia techniques-iPACK block (Interspace Between the Popliteal Artery and the Capsule of the posterior Knee) and the Biceps Femoris Short Head (BiFeS) block-when combined with an adductor canal block (ACB) in patients undergoing elective unilateral total knee arthroplasty (TKA). Effective postoperative analgesia is essential for early mobilization, enhanced recovery, and patient satisfaction after TKA. Although ACB provides good anterior knee analgesia while preserving quadriceps strength, additional posterior knee analgesia is often required.

The iPACK block is a commonly used technique that targets the posterior knee capsule, whereas the newer BiFeS block aims to provide more selective posterolateral sensory blockade with potentially reduced risk of motor involvement. However, comparative clinical data between these two techniques are limited.

The primary objective of this study is to evaluate the difference between the iPACK and BiFeS blocks in terms of Quality of Recovery-15 (QoR-15) scores at 24 hours postoperatively. Secondary objectives include comparisons of postoperative pain scores, opioid consumption, time to first analgesic request, quadriceps and anterior tibialis muscle strength, functional test performance, time to mobilization, active range of motion, and the incidence of adverse events.

A total of 74 adult patients scheduled for elective unilateral TKA under spinal anesthesia will be randomized in a 1:1 ratio into two groups: ACB + iPACK block or ACB + BiFeS block. All blocks will be performed under ultrasound guidance by an experienced anesthesiologist. Outcome assessments will be conducted by blinded investigators. The study aims to provide high-quality clinical evidence regarding the effectiveness of the BiFeS block compared to the widely used iPACK technique.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Age 18-75 years * Scheduled for elective primary unilateral total knee arthroplasty (TKA) * Planned spinal anesthesia * ASA physical status I-III * Ability to understand study procedures and provide written informed consent Exclusion Criteria: * Known allergy or hypersensitivity to local anesthetics or other study medications * Coagulopathy or current anticoagulant therapy * Severe hepatic, renal, or cardiac failure * History of neuropathic pain * Infection at the site of proposed nerve block * Pre-existing neuromuscular disorders in the lower extremities * Inability to cooperate or refusal to participate in the study * Pregnancy

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Ataturk University Erzurum Turkey (Türkiye) Recruiting

More Ataturk University trials in Turkey

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07248072 on ClinicalTrials.gov ↗ ← All trials in Turkey